CN111432882A - 对乙酰氨基酚-普瑞巴林组合和治疗疼痛的方法 - Google Patents

对乙酰氨基酚-普瑞巴林组合和治疗疼痛的方法 Download PDF

Info

Publication number
CN111432882A
CN111432882A CN201880078361.4A CN201880078361A CN111432882A CN 111432882 A CN111432882 A CN 111432882A CN 201880078361 A CN201880078361 A CN 201880078361A CN 111432882 A CN111432882 A CN 111432882A
Authority
CN
China
Prior art keywords
dosage form
unit dosage
liquid unit
pharmaceutical composition
acetaminophen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880078361.4A
Other languages
English (en)
Chinese (zh)
Inventor
瓦伦·库拉纳
杰克·马丁·利普曼
米兰·帕特尔
尤里·伊利乔夫
图沙尔·欣戈拉尼
库玛列什·索皮马斯
纳夫尼特·普瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nevaca Injection Co
Original Assignee
Nevaca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nevaca filed Critical Nevaca
Publication of CN111432882A publication Critical patent/CN111432882A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880078361.4A 2017-10-03 2018-10-02 对乙酰氨基酚-普瑞巴林组合和治疗疼痛的方法 Pending CN111432882A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762567384P 2017-10-03 2017-10-03
US62/567,384 2017-10-03
PCT/US2018/053864 WO2019070641A1 (en) 2017-10-03 2018-10-02 COMBINATIONS OF ACETAMINOPHENE-PRÉGABALINE AND METHODS OF TREATING PAIN

Publications (1)

Publication Number Publication Date
CN111432882A true CN111432882A (zh) 2020-07-17

Family

ID=65995245

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880078361.4A Pending CN111432882A (zh) 2017-10-03 2018-10-02 对乙酰氨基酚-普瑞巴林组合和治疗疼痛的方法

Country Status (6)

Country Link
US (2) US11547686B2 (https=)
EP (1) EP3691748A4 (https=)
JP (1) JP7249670B2 (https=)
CN (1) CN111432882A (https=)
CA (1) CA3075414A1 (https=)
WO (1) WO2019070641A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115475162A (zh) * 2022-10-18 2022-12-16 浙江震元制药有限公司 4-异丁基-2-吡咯烷酮在制备镇痛药物中的应用、一种镇痛药物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022178018A1 (en) * 2021-02-19 2022-08-25 Nevakar Injectables Inc. Liquid unit dosage forms for treatment of pain
WO2022256545A1 (en) * 2021-06-04 2022-12-08 Nevakar Injectables Inc. Injectable pregabalin formulations
GR1011104B (el) * 2024-12-18 2026-01-16 Ιουλια Τσετη Προγεμισμενη συριγγα υδατικου διαλυματος παρακεταμολης καταλληλη για ενεσιμη χορηγηση

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658919A (en) * 1993-04-16 1997-08-19 Mcneil-Ppc, Inc. Aqueous pharmaceutical suspension and process for preparation thereof
US20100279984A1 (en) * 2007-10-09 2010-11-04 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US20050004219A1 (en) 2003-07-01 2005-01-06 Medtronic, Inc. Pump systems including injectable gabapentin compositions
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
MX2007006091A (es) 2007-05-21 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante.
US20120245230A1 (en) * 2009-12-10 2012-09-27 Tecnimede-Sociedade Tecnico- Medicinal, S.A. Method and composition for preparing stable liquid formulations of paracetamol
EP2946767B1 (en) * 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
US20190029979A1 (en) * 2016-02-05 2019-01-31 Innopharma, Inc. Process of Manufacturing a Stable, Ready to Use Infusion Bag for an Oxidation Sensitive Formulation
WO2017177160A1 (en) 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658919A (en) * 1993-04-16 1997-08-19 Mcneil-Ppc, Inc. Aqueous pharmaceutical suspension and process for preparation thereof
US20100279984A1 (en) * 2007-10-09 2010-11-04 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115475162A (zh) * 2022-10-18 2022-12-16 浙江震元制药有限公司 4-异丁基-2-吡咯烷酮在制备镇痛药物中的应用、一种镇痛药物

Also Published As

Publication number Publication date
JP2020536089A (ja) 2020-12-10
EP3691748A4 (en) 2021-07-07
JP7249670B2 (ja) 2023-03-31
US20200230091A1 (en) 2020-07-23
WO2019070641A1 (en) 2019-04-11
US11547686B2 (en) 2023-01-10
CA3075414A1 (en) 2019-04-11
EP3691748A1 (en) 2020-08-12
US20230106270A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
US20230106270A1 (en) Acetaminophen-Pregabalin Combinations And Methods Of Treating Pain
JP5990832B2 (ja) デキスメデトミジンプレミックス製剤
HU226117B1 (en) Stable liquid paracetamol compositions
CA2886241A1 (en) Stable injectable pharmaceutical composition of epinephrine or salts thereof
CA2333310A1 (en) Use of tricyclic antidepressants for local analgesia
CN106456583B (zh) 用于治疗神经障碍的巴氯芬、阿坎酸和中链甘油三酯的组合
JP2014051528A (ja) エキソ−ｓ−メカミラミン製剤および治療におけるその使用
CN103179962A (zh) 丙二腈酰胺类似物在神经病理性疼痛中的用途
BR112021004331A2 (pt) tratamento de dor pós-cirúrgica
WO2019074701A1 (en) STABLE OPIOID ANTAGONIST SOLUTIONS AT LOW TEMPERATURE
PT100850B (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
KR20160070077A (ko) 안구내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조 방법
KR20070083579A (ko) 염증 질환 및 통증의 치료
KR20190035927A (ko) 안구 내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조방법
US12005066B2 (en) Cobinamide compounds as a cyanide, sulfide, or methane-thiol antidote
US20190336463A1 (en) Levothyroxine liquid formulations
CA3190205C (en) Analgesic and antipruritic pharmaceutical composition and application thereof
RS20050752A (sr) Kombinacija makrolida i lokalnog anestetika za tretman dermatoloških oboljenja
TW200808804A (en) Mirtazapine for the treatment of neuropathic pain
JP2006522060A (ja) マクロライド系免疫調節剤を含む、医薬組成物
WO2025253095A1 (en) Phenobarbital oral composition and method of manufacture/use thereof
JP2022546772A (ja) アポモルフィン製剤
HK1251983A1 (zh) 親脂性藥劑的改進的胃腸外製劑以及製備和使用其的方法
HK1233960A1 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
BR102016030392A2 (pt) composição farmacêutica tópica, uso e método de tratamento da dor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20211015

Address after: New jersey, USA

Applicant after: Nevaca injection Co.

Address before: New jersey, USA

Applicant before: Nevaca

TA01 Transfer of patent application right
AD01 Patent right deemed abandoned

Effective date of abandoning: 20240319

AD01 Patent right deemed abandoned